|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 CASI Pharmaceuticals, Inc. 10-Q 9/30/22 74:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.67M
2: EX-10.1 Material Contract HTML 289K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 74K
13: R2 Unaudited Condensed Consolidated Balance Sheets HTML 126K
14: R3 Unaudited Condensed Consolidated Balance Sheets HTML 43K
(Parenthetical)
15: R4 Unaudited Condensed Consolidated Statements of HTML 147K
Operations and Comprehensive Loss
16: R5 Unaudited Condensed Consolidated Statements of HTML 81K
Stockholders' Equity
17: R6 Unaudited Condensed Consolidated Statements of HTML 141K
Cash Flows
18: R7 Description of Business HTML 27K
19: R8 License and Distribution Agreements HTML 41K
20: R9 Summary of Significant Accounting Policies HTML 26K
21: R10 Revenue Related Information HTML 25K
22: R11 Investment in Equity Securities, at Fair Value and HTML 192K
Long-term Investments
23: R12 Inventories HTML 22K
24: R13 Property, Plant and Equipment HTML 41K
25: R14 Leases HTML 63K
26: R15 Accrued and Other Current Liabilities, and Other HTML 52K
Liabilities
27: R16 Bank Borrowings HTML 21K
28: R17 Redeemable Noncontrolling Interest HTML 38K
29: R18 Stockholders' Equity HTML 31K
30: R19 Net Loss Per Share HTML 58K
31: R20 Stock-Based Compensation HTML 38K
32: R21 Income Taxes HTML 25K
33: R22 Fair Value Measurements HTML 106K
34: R23 Related Party Transactions HTML 24K
35: R24 Commitments and Contingencies HTML 27K
36: R25 Subsequent Events HTML 23K
37: R26 Summary of Significant Accounting Policies HTML 31K
(Policies)
38: R27 Investment in Equity Securities, at Fair Value and HTML 189K
Long-term Investments (Tables)
39: R28 Property, Plant and Equipment (Tables) HTML 39K
40: R29 Leases (Tables) HTML 63K
41: R30 Accrued and Other Current Liabilities, and Other HTML 51K
Liabilities (Tables)
42: R31 Redeemable Noncontrolling Interest (Tables) HTML 37K
43: R32 Net Loss Per Share (Tables) HTML 56K
44: R33 Stock-Based Compensation (Tables) HTML 36K
45: R34 Fair Value Measurements (Tables) HTML 99K
46: R35 Description of Business (Details) HTML 30K
47: R36 License and Distribution Agreements (Details) HTML 112K
48: R37 Investment in Equity Securities, at Fair Value and HTML 32K
Long-term Investments - Summary of Investments
(Details)
49: R38 Investment in Equity Securities, at Fair Value and HTML 58K
Long-term Investments - Summary of Long-term
investments (Details)
50: R39 Investment in Equity Securities, at Fair Value and HTML 57K
Long-term Investments (Details)
51: R40 Inventories (Details) HTML 25K
52: R41 Property, Plant and Equipment (Details) HTML 36K
53: R42 Leases - (Details) HTML 39K
54: R43 Leases - Right of Use Assets and Liabilities HTML 36K
(Details)
55: R44 Leases - Supplemental Cash Flow (Details) HTML 25K
56: R45 Leases - Future Undiscounted Cash Flows (Details) HTML 38K
57: R46 Accrued and Other Current Liabilities, and Other HTML 50K
Liabilities (Details)
58: R47 Bank Borrowings (Details) HTML 36K
59: R48 Redeemable Noncontrolling Interest - Changes in HTML 30K
Redeemable Noncontrolling Interest (Details)
60: R49 Stockholders' Equity (Details) HTML 51K
61: R50 Net Loss Per Share (Details) HTML 24K
62: R51 Net Loss Per Share - Basic and diluted net loss HTML 54K
per share computation (Details)
63: R52 Stock-Based Compensation - Compensation Expense HTML 29K
(Details)
64: R53 Income Taxes (Details) HTML 22K
65: R54 Fair Value Measurements - Financial and HTML 47K
Non-Financial Assets and Liabilities (Details)
66: R55 Fair Value Measurements (Details) HTML 31K
67: R56 Related Party Transactions (Details) HTML 33K
68: R57 Commitments and Contingencies (Details) HTML 47K
69: R58 Subsequent Event (Details) HTML 25K
72: XML IDEA XML File -- Filing Summary XML 132K
70: XML XBRL Instance -- casi-20220930x10q_htm XML 1.82M
71: EXCEL IDEA Workbook of Financial Reports XLSX 117K
8: EX-101.CAL XBRL Calculations -- casi-20220930_cal XML 163K
9: EX-101.DEF XBRL Definitions -- casi-20220930_def XML 475K
10: EX-101.LAB XBRL Labels -- casi-20220930_lab XML 850K
11: EX-101.PRE XBRL Presentations -- casi-20220930_pre XML 719K
7: EX-101.SCH XBRL Schema -- casi-20220930 XSD 158K
73: JSON XBRL Instance as JSON Data -- MetaLinks 332± 503K
74: ZIP XBRL Zipped Folder -- 0001558370-22-017615-xbrl Zip 320K
Exhibit 32.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wei-Wu He, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report. |
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.
| |
Date: November 14, 2022 | /s/ Wei-Wu He |
| |
| Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. 424B3 1:1.7M Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. (DE) DEF 14A 3/20/23 1:1.7M Toppan Merrill/FA 2/09/23 CASI Pharmaceuticals, Inc. F-4/A 1:924K Toppan Merrill/FA 1/31/23 CASI Pharmaceuticals, Inc. F-4 22:2.7M Toppan Merrill/FA |